MX2016001155A - Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion. - Google Patents

Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion.

Info

Publication number
MX2016001155A
MX2016001155A MX2016001155A MX2016001155A MX2016001155A MX 2016001155 A MX2016001155 A MX 2016001155A MX 2016001155 A MX2016001155 A MX 2016001155A MX 2016001155 A MX2016001155 A MX 2016001155A MX 2016001155 A MX2016001155 A MX 2016001155A
Authority
MX
Mexico
Prior art keywords
granules
rifapentine
isoniazid
preparation
pharmaceutical composition
Prior art date
Application number
MX2016001155A
Other languages
English (en)
Inventor
Prajapati Dilip
Prasad Kum
Khullar Praveen
Kumar Ramesh
Kumar Shakti
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51211798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016001155(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2016001155A publication Critical patent/MX2016001155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica oral de dosis fija en una forma de un comprimido dispersable para uso en el tratamiento de la tuberculosis, comprendiendo dicha composición farmacéutica oral: a) gránulos que comprenden isoniazid y al menos un excipiente intragranular; b) gránulos que comprenden rifapentina y al menos un excipiente intragranular; y c) al menos un excipiente extragranular; y a su proceso de preparación.
MX2016001155A 2013-07-26 2014-07-22 Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion. MX2016001155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3342CH2013 2013-07-26
PCT/EP2014/065762 WO2015011162A1 (en) 2013-07-26 2014-07-22 Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation

Publications (1)

Publication Number Publication Date
MX2016001155A true MX2016001155A (es) 2016-04-29

Family

ID=51211798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001155A MX2016001155A (es) 2013-07-26 2014-07-22 Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion.

Country Status (18)

Country Link
US (1) US9814680B2 (es)
EP (1) EP3024444A1 (es)
JP (2) JP2016539110A (es)
CN (1) CN105407876B (es)
AU (1) AU2014295099B2 (es)
CA (1) CA2918528A1 (es)
CL (1) CL2016000183A1 (es)
HK (1) HK1218861A1 (es)
IL (1) IL243369A0 (es)
MX (1) MX2016001155A (es)
PE (1) PE20160245A1 (es)
PH (1) PH12016500119A1 (es)
RU (1) RU2694056C2 (es)
SA (1) SA516370446B1 (es)
SG (2) SG10201803996WA (es)
TW (1) TWI630911B (es)
WO (1) WO2015011162A1 (es)
ZA (1) ZA201600110B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3024445B1 (en) 2013-07-26 2019-01-09 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
EP4240392A1 (en) * 2020-11-09 2023-09-13 Realta Life Sciences, Inc. Peptide formulations and methods of use
CN112730657A (zh) * 2020-12-18 2021-04-30 卓和药业集团有限公司 利福喷丁含量的分析检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) * 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
PL355844A1 (en) 2000-08-09 2004-05-31 Panacea Biotec Limited Novel pharmaceutical compositions of anti-tubrcular drugs and process for their preparation
EP1334716A4 (en) * 2000-10-16 2009-04-29 Daiichi Seiyaku Co MEDICAL COMPOSITIONS THAT CAN RAPIDLY DISINTEGRATE IN ORAL CAVITY AND METHOD OF PRODUCING THE SAME
WO2002087547A1 (en) 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
US20050059719A1 (en) 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
TW201233389A (en) 2005-10-05 2012-08-16 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
US20090295921A1 (en) * 2005-10-12 2009-12-03 Pioneer Corporation Vehicle-mounted photographing device and method of measuring photographable range of vehicle-mounted camera
CN1989966B (zh) 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 含利福平和异烟肼的药物组合物
CN1857280A (zh) * 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
KR101197277B1 (ko) * 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
RU2012105674A (ru) 2009-07-31 2013-09-10 Кадила Фармасьютикалз Лтд. Фармацевтическая композиция изониазида
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
WO2012013756A2 (fr) 2010-07-28 2012-02-02 Laboratoires Pharma 5 Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
PE20160520A1 (es) 2013-07-26 2016-05-31 Sanofi Sa Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
EP3024445B1 (en) 2013-07-26 2019-01-09 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation

Also Published As

Publication number Publication date
CL2016000183A1 (es) 2016-07-01
HK1218861A1 (zh) 2017-03-17
SA516370446B1 (ar) 2018-09-13
US9814680B2 (en) 2017-11-14
ZA201600110B (en) 2017-04-26
SG11201510732VA (en) 2016-01-28
TW201601723A (zh) 2016-01-16
US20160184231A1 (en) 2016-06-30
SG10201803996WA (en) 2018-06-28
PE20160245A1 (es) 2016-05-10
JP2016539110A (ja) 2016-12-15
CN105407876B (zh) 2019-08-30
PH12016500119A1 (en) 2016-04-25
AU2014295099A1 (en) 2016-02-11
AU2014295099B2 (en) 2019-07-11
JP6476331B2 (ja) 2019-02-27
EP3024444A1 (en) 2016-06-01
IL243369A0 (en) 2016-02-29
WO2015011162A1 (en) 2015-01-29
RU2016106328A (ru) 2017-08-31
CN105407876A (zh) 2016-03-16
CA2918528A1 (en) 2015-01-29
RU2694056C2 (ru) 2019-07-09
JP2018123147A (ja) 2018-08-09
TWI630911B (zh) 2018-08-01

Similar Documents

Publication Publication Date Title
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
IN2013MU03583A (es)
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
PH12015500823A1 (en) Modified release formulations for oprozomib
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
IN2013MU03428A (es)
MX2018013428A (es) Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina.
IN2013MU02110A (es)
MX2018004776A (es) Compuestos oxaazaespiricos con actividad contral el dolor.
IN2013MU02111A (es)
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток
EA201790387A1 (ru) Фармацевтическая композиция для лечения острой зубной боли или боли в челюсти
IN2014DE00822A (es)
IN2013MU01241A (es)
IN2013MU01242A (es)